AMACR immunohistochemistry: what your pathology result means

AMACR stands for alpha-methylacyl-CoA racemase and may also appear on a report as P504S. The stain is commonly used when examining prostate tissue, although AMACR can be present in cells from other organs and in some non-cancerous changes.

A positive result means the sampled cells took up the AMACR stain. In a prostate biopsy, that finding can support a diagnosis of prostate cancer when the cell shape, tissue arrangement, and other stains point in the same direction. AMACR positivity alone cannot establish where a tumour began or whether a suspicious area is malignant.

A negative result means convincing staining was not seen in the tested tissue. Some cancers show weak, patchy, or absent AMACR staining, so a negative stain cannot exclude cancer on its own. Pathologists may compare AMACR with basal-cell markers and the appearance of the glands under the microscope.

The wording matters: terms such as strong, weak, focal, diffuse, or equivocal describe the staining pattern, not a cancer stage. The final diagnosis or comment section of the pathology report explains how the stain contributed to the overall interpretation.

Review the final diagnosis rather than reading the AMACR line in isolation. Your clinician can connect the pathology findings with why the biopsy was taken, the imaging or examination findings, and any relevant blood tests.

If the report is uncertain, the next step may be deeper tissue sections, additional immunohistochemical stains, review by a pathologist with experience in that organ, or another sample. These steps clarify the tissue pattern; they are not automatically a sign that cancer has been confirmed.

The AMACR stain is performed in the laboratory and does not create symptoms in your body. Contact the team that arranged the biopsy if you have fever, increasing redness or swelling at the sampling site, worsening pain, heavy bleeding, or difficulty passing urine after a prostate biopsy.

Seek urgent care for severe bleeding, fainting, new confusion, chest pain, or sudden difficulty breathing. These warning signs relate to your health or the tissue-sampling procedure, not to whether AMACR staining was positive or negative.

Ask: What is the final diagnosis? Was AMACR staining strong, weak, or limited to part of the sample? Which other stains or microscopic features support the interpretation? Is the sample adequate, and would specialist pathology review change the next step?